Video
Dr. Lallas on Understanding Immunotherapy in GU Malignancies
Author(s):
In Partnership With:
Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.
Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary (GU) malignancies.
The rise of multidisciplinary care in GU malignancies means that it is no longer solely the job of the oncologists to administer novel agents such as immunotherapy.
Lallas says that this rise in multidisciplinary care, in addition to workforce shortages, means that it is very important for urologists and advanced practice providers to understand chemotherapy and immunotherapy regimens for GU malignancies.
